Search Results for "Sunitinib"

17:11 EDT 25th October 2014 | BioPortfolio

Matching Channels

None

Matching News

Sunitinib: First Drug Active in Refractory Meningioma

In refractory atypical/malignant meningioma, sunitinib is associated with good progression-free survival, but also with high toxicity rates. Medscape Medical News

Sunitinib or Everolimus First-Line for Kidney Cancer?

A phase 2 randomized comparator trial has found that first-line everolimus is not as effective as first-line sunitinib, and has a different toxicity profile. Medscape Medical News

Sunitinib malate (Sutent) for renal cell carcinoma – adjuvant therapy

Sunitinib malate (Sutent) is an oral small-molecule inhibitor with selectivity for platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1,...

First-line sunitinib superior to everolimus for metastatic RCC

Results for the RECORD-3 trial support the current strategy of first-line sunitinib followed by second-line everolimus for the treatment of patients with metastatic renal cell carcinoma.

Alternative sunitinib treatment schedules for mRCC may be worth the switch

Some patients with metastatic renal cell carcinoma who are switched from a traditional sunitinib treatment schedule to an alternative schedule fare better on survival measures and suffer fewer adverse...

Genetic variants alter chance of sunitinib dose reduction

Scientists have identified genetic variants that reduce the likelihood of sunitinib dose reduction in patients with metastatic renal cell carcinoma.

Immature blood vessels linked to poor sunitinib response

Patients with clear-cell renal cell carcinoma with relatively mature blood vessels respond better to sunitinib and have fewer metastatic sites than those with immature vessels, a study has found.

[News] Sunitinib still first-line therapy for metastatic renal cancer

Everolimus (an mTOR inhibitor) does not yield better results compared with sunitinib (a VEGFR tyrosine kinase inhibitor) as first-line therapy in patients with metastatic renal-cell carcinoma, new res...

Matching PubMed Articles

Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinoma.

Sunitinib is a multiple tyrosine kinase receptor inhibitor that is approved for the treatment of metastatic renal cell carcinoma (RCC). However, neither an appropriate dose nor dosing schedule of suni...

A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma.

Sunitinib has become a standard treatment agent for metastatic renal cell carcinoma (RCC) for several years. However, various adverse events have been reported. We present a rare adverse effect of hyp...

Contribution of Plasma Proteins, Albumin and Alpha 1-Acid Glycoprotein, to Pharmacokinetics of a Multi-targeted Receptor Tyrosine Kinase Inhibitor, Sunitinib, in Analbuminemic Rats.

The present study investigated the role of the major plasma proteins, albumin and α1-acid glycoprotein (AAG), in the pharmacokinetics of sunitinib using Sprague-Dawley (SD) rats and analbuminemic rat...

Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.

Sunitinib is an oral multitargeted tyrosine kinase inhibitor used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse effects (RAEs) of sunitinib have not been investigated....

Sunitinib Achieved Fast and Sustained Control of VIPoma Symptoms.

Background: VIPomas are rare functioning neuroendocrine tumors (NET). Vasointestinal peptide (VIP) overproduction leads to the Verner-Morrison syndrome, whose management is challenging when refractory...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement